In Re Dane K. Fisher and Raghunath v. Lalgudi Case Brief
Complete case briefs with LSD+
Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: An inventor sought a patent for five Expressed Sequence Tags (ESTs), which are fragments of genes with unknown functions. The court denied the patent, holding that the ESTs lacked the required “specific and substantial utility” and were merely tools for further research.
Legal Significance: This case established that gene fragments like ESTs, with no known function for their corresponding genes, are not patentable. It affirmed the PTO’s “specific and substantial utility” standard for biotechnological inventions, treating them as unpatentable research intermediates rather than finished inventions.
In Re Dane K. Fisher and Raghunath v. Lalgudi Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Applicants Dane K. Fisher and Raghunath Lalgudi filed a patent application for five purified nucleic acid sequences known as Expressed Sequence Tags (ESTs). These ESTs were derived from genes in maize plants, but the precise structure and biological function of the full genes and the proteins they encoded were unknown at the time of filing. The application disclosed seven potential uses for the ESTs, including serving as molecular markers for genome mapping, measuring mRNA levels, providing primers for PCR, identifying polymorphisms, and isolating gene promoters. These asserted uses were general research applications not unique to the five claimed ESTs but applicable to virtually any EST. The patent examiner rejected the application for lack of utility under 35 U.S.C. § 101, reasoning that the disclosed uses were not specific to the claimed ESTs and were not substantial because they constituted starting points for further research rather than providing a present, real-world benefit. The Board of Patent Appeals and Interferences affirmed the rejection, and the applicants appealed to the Federal Circuit.
Court Holding & Legal Precedent
Issue: Does an invention consisting of Expressed Sequence Tags (ESTs) satisfy the utility requirement of 35 U.S.C. § 101 when the functions of the underlying genes are unknown and the asserted uses are general research applications?
No. The court held that the claimed ESTs lack a specific and Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
IRAC Legal Analysis
About IRAC analysis
IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.
Legal Issue
Does an invention consisting of Expressed Sequence Tags (ESTs) satisfy the utility requirement of 35 U.S.C. § 101 when the functions of the underlying genes are unknown and the asserted uses are general research applications?
Conclusion
This decision solidified a stringent utility standard for genomic inventions, preventing the Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
Legal Rule
To satisfy the utility requirement of 35 U.S.C. § 101, a claimed Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
Legal Analysis
The court's analysis centered on the "specific and substantial utility" test from Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
Flash-to-Full Case Opinions
Flash Summary
- The Federal Circuit held that Expressed Sequence Tags (ESTs) are not